Myovant Sciences
2000 Sierra Point Parkway, Suite 900
Brisbane, CA 94005
United States
Tel: 650-392-0222
Website: https://www.myovant.com/
About Myovant Sciences
We aspire to be the leading healthcare company focused on redefining care for women’s health and prostate cancer. Our experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and men suffering from prostate cancer. We strive to improve the lives of millions of people, while building an innovative, dynamic, and collaborative company where employees thrive.
161 articles with Myovant Sciences
-
Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources
11/16/2022
Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources.
-
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - November 16, 2022
11/16/2022
Myovant Sciences, a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, announced that it approved equity awards for 18 new employees with a grant date of November 15, 2022 pursuant to Myovant’s 2020 Inducement Plan.
-
Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022
10/26/2022
Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced financial results for the second quarter of fiscal year 2022 and provided other corporate updates.
-
Myovant Sciences agreed to be acquired by Sumitovant Biopharma for $2.9 billion - three weeks after turning down a previous offer.
-
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement
10/24/2022
Sumitovant Biopharma Ltd., in conjunction with parent company Sumitomo Pharma Co., Ltd., and Myovant Sciences announced that they have entered into a definitive agreement pursuant to which Sumitovant will acquire all outstanding shares of Myovant not already owned by Sumitovant for $27.00 per share in cash.
-
Myovant Sciences Cancels Second Quarter Earnings Conference Call
10/24/2022
Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Eastern Time.
-
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - October 18, 2022
10/18/2022
Myovant Sciences, a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, announced that it approved equity awards for 10 new employees with a grant date of October 17, 2022 pursuant to Myovant’s 2020 Inducement Plan.
-
Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on October 26, 2022
10/14/2022
Myovant Sciences, announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter, ended September 30, 2022.
-
Sumitovant Biopharma and Sumitomo Pharma Announce Offer to Acquire Outstanding Shares of Myovant Sciences
10/3/2022
Sumitovant Biopharma Ltd., in conjunction with parent company Sumitomo Pharma Co., Ltd., announced it has submitted a non-binding proposal to the Audit Committee of the Board of Directors of Myovant Sciences Ltd. offering to acquire all outstanding shares of Myovant not already owned by Sumitovant for $22.75 per share in cash.
-
Myovant Sciences formed a special committee of independent directors to assess Sumitovant Biopharma's offer after Sumitovant announced plans to acquire the company.
-
Myovant Sciences Special Committee of Board Confirms Receipt of Preliminary, Non-binding Proposal from Sumitovant Biopharma and Sumitomo Pharma to Acquire Remaining Shares
10/2/2022
Myovant Sciences Ltd. confirmed that it has received a preliminary, non-binding proposal from Sumitovant Biopharma Ltd. and Sumitomo Pharma Co., Ltd. to acquire the remaining shares of the Company that Sumitovant does not currently hold, for a price of $22.75 per share in cash.
-
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - September 16, 2022
9/16/2022
Myovant Sciences announced that it approved equity awards for 7 new employees with a grant date of September 15, 2022 pursuant to Myovant’s 2020 Inducement Plan.
-
Myovant Sciences to Participate at Upcoming September 2022 Investor Conferences
9/2/2022
Myovant Sciences announced that David Marek, Chief Executive Officer of Myovant Sciences, Inc., and Uneek Mehra, Chief Financial and Business Officer, will participate in the following upcoming investor conferences.
-
NCCN Announces Collaboration with Myovant Sciences and Pfizer to Support Projects to Understand and Mitigate Cardiovascular Risk in Patients with Prostate Cancer
8/30/2022
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced a collaboration with Pfizer and Myovant Sciences to fund research projects seeking to improve cardiovascular management of patients with prostate cancer being treated with androgen-deprivation therapy (ADT).
-
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - Aug 16, 2022
8/16/2022
Myovant Sciences, a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, announced that it approved equity awards for 11 new employees with a grant date of August 15, 2022 pursuant to Myovant’s 2020 Inducement Plan.
-
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
8/5/2022
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a one-pill, once-a-day therapy for the management of moderate to severe pain associated with endometriosis in pre-menopausal women, with a treatment duration of up to 24 months.
-
The end of July is busy for the FDA, with Coherus, Sanofi, Acadia, Myovant and Pfizer having PDUFA dates filling the calendar. Here’s a look.
-
Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022
7/27/2022
Myovant Sciences announced financial results for the first quarter of fiscal year 2022 and provided other corporate updates.
-
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - July 18, 2022
7/18/2022
Myovant Sciences announced that it approved equity awards for 9 new employees with a grant date of July 15, 2022 pursuant to Myovant’s 2020 Inducement Plan.
-
Myovant Sciences to Host First Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on July 27, 2022
7/13/2022
Myovant Sciences, announced it will host a webcast and conference call to discuss corporate updates and financial results for its first fiscal quarter, ended June 30, 2022.